Pfenex (PFNX) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Pfenex Reports Second Quarter 2015 Results and Provides Business Update
August 13, 2015 7:47 AM EDTSAN DIEGO, Aug. 13, 2015 /PRNewswire/ --Â Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today reported financial results for the second quarter ended June 30, 2015 and provided a business update.
"Pfenex made significant progress in the second quarter of 2015, and we expect to provide key pipeline updates over the course of 2015 and into 2016. Specifically, we look forward to updating you on progress... More
